Andere talen MediWound Ltd.

Aandelen

MDWD

IL0011316309

Beurs gesloten - Nasdaq Andere beurzen 22:00:00 30-04-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
18,61 ^USD	-3,17%		+13,41%	+82,99%

21/03	MediWound Ltd. Geeft omzetbegeleiding voor het jaar 2025 en 2026	CI
21/03	Transcript : MediWound Ltd., Q4 2023 Earnings Call, Mar 21, 2024

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

MediWound to Present New Data from EscharEx® Phase II Studies at Three Leading Wound Care Conferences	25/04
MediWound to Present New Data from EscharEx® Phase II Studies at Three Leading Wound Care Conferences	25/04
MediWound Ltd. Provides Revenue Guidance for the Year 2025 and 2026	21/03
MediWound Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	21/03
Earnings Flash (MDWD) MEDIWOUND Posts Q4 Revenue $5.3M, vs. Street Est of $5.3M	21/03
MediWound: Q4 Earnings Snapshot	21/03
MediWound Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Company Update	21/03
MediWound Ltd. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	21/03
MediWound to Report Fourth Quarter and Full Year 2023 Financial Results	14/03
MediWound to Report Fourth Quarter and Full Year 2023 Financial Results	14/03
Sector Update: Health Care Stocks Mixed Late Afternoon	12/02
MediWound Shares Rise After Positive Results From EscharEx Comparison Study	12/02
MediWound Announces Positive Results in Head-to-Head Comparison of EscharEx® vs. SANTYL® within the ChronEx Phase II Randomized Controlled Study	12/02
Mediwound Ltd. Announces Positive Results in Head-To-Head Comparison of Escharex® Vs. Santyl® Within the Chronex Phase Ii Randomized Controlled Study	12/02
MediWound to Participate in Two Upcoming Investor Conferences	05/02
MediWound to Participate in Two Upcoming Investor Conferences	05/02
MediWound's NexoBrid Application to Include Pediatric Patients Accepted for Review by FDA	09/01
MediWound Announces that FDA has Accepted for Review the Supplement to the NexoBrid BLA to Include Pediatric Patients with Severe Thermal Burns	09/01
MediWound Announces that FDA has Accepted for Review the Supplement to the NexoBrid BLA to Include Pediatric Patients with Severe Thermal Burns	09/01
Mediwound Announces That FDA Has Accepted for Review the Supplement to the Nexobrid BLA to Include Pediatric Patients with Severe Thermal Burns	09/01

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen MediWound Ltd.

Aandelen

MDWD

IL0011316309

Andere talen

Filters